Syndax Pharmaceuticals (SNDX) Free Cash Flow (2015 - 2026)

Syndax Pharmaceuticals' Free Cash Flow history runs 12 years deep, the most recent figure standing at -$50.3 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 47.1% year-over-year to -$50.3 million in Q1 2026; TTM through Mar 2026 was -$278.2 million, a 2.9% increase from a year earlier, with the FY2025 full-year figure at -$323.2 million, down 17.56% from the prior year.
• Free Cash Flow rose to -$50.3 million in Q1 2026 per SNDX's latest filing, from -$69.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$22.9 million in Q4 2022 and bottomed at -$95.2 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$50.3 million (2026), against an average of -$55.4 million.
• Across the five-year window, Free Cash Flow tumbled 122.73% in 2022 and surged 47.1% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$22.9 million in 2022, then slumped by 80.61% to -$41.3 million in 2023, then plunged by 38.79% to -$57.4 million in 2024, then retreated by 21.18% to -$69.5 million in 2025, then grew by 27.61% to -$50.3 million in 2026.
• Per Business Quant, the three latest SNDX Free Cash Flow figures stand at -$50.3 million (Q1 2026), -$69.5 million (Q4 2025), and -$70.5 million (Q3 2025).